Results 181 to 190 of about 17,175,483 (375)

Nodular immunocyte-derived (AL) amyloidosis in the trachea of a dog [PDF]

, 2004
M. Faulkner Besancon, Brian A. Stacy, Andrew E. Kyles, Peter F. Moore, William Vernau, Sean D. Smarick, Liberty A. Rasor   +6 more
openalex   +1 more source

Sharpening therapeutic strategy in AL amyloidosis [PDF]

, 2004
Giampaolo Merlini
openalex   +1 more source

Artificial intelligence‐based echocardiographic assessment for monitoring disease progression in transthyretin cardiac amyloidosis

European Journal of Heart Failure, EarlyView.
Artificial intelligence (AI)‐based estimation of stroke volume for risk prediction in amyloid transthyretin cardiomyopathy (ATTR‐CM). ATTRv, hereditary transthyretin amyloidosis; ATTRwt, wild‐type transthyretin amyloidosis; CI, confidence interval; HR, hazard ratio; IQR, interquartile range; LVOT‐VTI, left ventricular outflow tract velocity‐time ...
Lucia Venneri, Alberto Aimo, Aldostefano Porcari, Irem Sezer, Adam Ioannou, Awais Sheikh, Josephine Mansell, Yousuf Razvi, Surabhi Bhaskar Iyer, Ana Martinez‐Naharro, Francesco Bandera, Sze Chi Lim, Matthew Frost, Justin Ezekowitz, Carolyn S.P. Lam, William Moody, Carol Whelan, Helen Lachmann, Ashutosh Wechelakar, Michele Emdin, Philip N. Hawkins, Scott David Solomon, Julian D. Gillmore, Marianna Fontana   +23 more
wiley   +1 more source

AL-amyloidosis and light-chain deposition disease light chains induce divergent phenotypic transformations of human mesangial cells [PDF]

, 2004
John Keeling, Jiamin Teng, Guillermo A. Herrera   +2 more
openalex   +1 more source

Amiloidose renal: classificação de 102 casos consecutivos [PDF]

, 2014
Amyloidoses are a group of heterogeneous diseases classified according to the nature of their causative amyloid proteins. Commonly, paraffin-embedded tissue is used for the typing of amyloid by immunohistochemistry.
Lobato, L., Moreira, L., Oliveira, J., Pereira, P., Pinho-Costa, P., Sampaio, S., Tavares, I., Vaz, R., Vizcaíno, J.   +8 more
core  

Efficacy and safety of vutrisiran in transthyretin amyloid cardiomyopathy across the age spectrum: The HELIOS‐B trial

European Journal of Heart Failure, EarlyView.
Summary of the HELIOS‐B trial design. Right: Forest (top) and spline (bottom) plots demonstrating the effect of vutrisiran versus placebo on clinical outcomes across age groups in HELIOS‐B. Age‐stratified outcomes with vutrisiran in transthyretin amyloid cardiomyopathy.
Awais Sheikh, Zi Michael Miao, Brian Claggett, Pablo Garcia‐Pavia, Francesco Cappelli, Emre Aldinc, Julian Gillmore, Scott D. Solomon, Marianna Fontana   +8 more
wiley   +1 more source

AL-amyloidosis is underdiagnosed in renal biopsies [PDF]

, 2004
Lea Novak, W.J. Cook, Guillermo A. Herrera, Paul W. Sanders   +3 more
openalex   +1 more source

Epidemiology of Systemic Light-Chain (AL) Amyloidosis

Lymphatics
Systemic light-chain (AL) amyloidosis is a challenging, complex and heterogeneous disease. AL amyloidosis is classified under the category of plasma cell neoplasms and other diseases with paraproteins in the fifth edition of the World Health Organization
Rafael Ríos-Tamayo
doaj   +1 more source

The great simulator [PDF]

, 1993
Cardiac myxoma often simulates multisystem disease and initially defies diagnosis. In this paper, we present three cases of cardiac myxoma in adults.
Aquilina, Oscar, Fenech, Frederick F., Mallia, Carmel   +2 more
core  

Microvascular obstruction in cardiac amyloidosis

European Journal of Heart Failure, EarlyView.
Lucrezia Netti, Adam Ioannou, Ana Martinez‐Naharro, Yousuf Razvi, Aldostefano Porcari, Lucia Venneri, Viviana Maestrini, Dan Knight, Ruta Virsinskaite, Muhammad U. Rauf, Tushar Kotecha, Rishi K. Patel, Ashutosh Wechelakar, Helen Lachmann, Peter Kellman, Charlotte Manisty, James Moon, Philip N. Hawkins, Julian D. Gillmore, Marianna Fontana   +19 more
wiley   +1 more source